新辅助化疗联合间隔减瘤术治疗晚期卵巢癌的临床疗效

发布时间：2018-11-07 09:32

【摘要】：目的探讨新辅助化疗联合间隔减瘤术治疗晚期卵巢癌的临床疗效。方法选取2009年1月至2011年10月间新疆自治区人民医院收治的60例晚期卵巢癌患者,采用随机数字表法分为观察组和对照组,每组30例。观察组患者采用新辅助化疗联合间隔减瘤术,对照组患者采用直接肿瘤减灭术。对比两组患者肿瘤细胞减灭术成功率、围手术期情况、化疗不良反应、术后3年和5年生存率。结果观察组患者残留病灶1cm者19例(63.3%),对照组患者残留病灶1cm者10例(33.3%);观察组患者手术时间、术中出血量和输血例数均显著少于对照组,组间比较差异均有统计学意义(均P0.05)。观察组患者术后胃肠功能恢复较快,排气时间比对照组患者短,差异有统计学意义(P0.05)。观察组患者术后发生并发症4例(2例肠梗阻,1例肠道损伤,1例切口愈合不佳),并发症发生率为13.3%。对照组患者发生并发症11例(肠梗阻4例,输尿管损伤3例,切口愈合不佳2例,深静脉血栓形成2例),并发症发生率为36.7%,两组比较,差异有统计学意义(P0.05)。观察组患者不良反应发生率明显较低,3年和5年生存率分别为83.3%和60.0%,对照组患者分别为53.3%和26.7%,差异有统计学意义(P0.05)。结论新辅助化疗联合间隔减瘤术治疗晚期卵巢癌可减少术中出血量和术后并发症的发生,缩短手术时间,延长患者术后生存时间。
[Abstract]:Objective to investigate the clinical effect of neoadjuvant chemotherapy combined with septal tumor reduction in the treatment of advanced ovarian cancer. Methods 60 patients with advanced ovarian cancer admitted in Xinjiang people's Hospital from January 2009 to October 2011 were randomly divided into observation group (n = 30) and control group (n = 30). The patients in the observation group were treated with neoadjuvant chemotherapy combined with septal tumor reduction, while the patients in the control group were treated with direct tumor reduction. The success rate of tumor cell reduction, perioperative condition, adverse reaction of chemotherapy, 3-year and 5-year survival rate were compared between the two groups. Results 1cm was found in 19 patients (63.3%) in the observation group and in 10 patients (33.3%) in the control group. The operative time, intraoperative blood loss and blood transfusion in the observation group were significantly less than those in the control group, and the differences between the two groups were statistically significant (P0.05). The patients in the observation group recovered their gastrointestinal function more quickly and the exhaust time was shorter than that in the control group (P0.05). In the observation group, complications occurred in 4 cases (2 cases of intestinal obstruction, 1 case of intestinal injury and 1 case of poor wound healing). The incidence of complications was 13.3%. There were 11 cases of complications (4 cases of intestinal obstruction, 3 cases of ureteral injury, 2 cases of poor wound healing and 2 cases of deep venous thrombosis) in the control group. The incidence of complications was 36.7%. The difference was statistically significant (P0.05). The incidence of adverse reactions in the observation group was significantly lower, the 3-year and 5-year survival rates were 83.3% and 60.0%, respectively, while those in the control group were 53.3% and 26.7%, respectively. The difference was statistically significant (P0.05). Conclusion Neoadjuvant chemotherapy combined with septal tumor reduction can reduce the amount of intraoperative bleeding and postoperative complications, shorten the operative time and prolong the postoperative survival time of patients with advanced ovarian cancer.
【作者单位】：新疆自治区人民医院妇科;
【分类号】：R737.31

【相似文献】